PMID- 1281055
OWN - NLM
STAT- MEDLINE
DCOM- 19930108
LR  - 20190509
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 90
IP  - 3
DP  - 1992 Dec
TI  - Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes 
      in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
PG  - 368-75
AB  - Bispecific antibodies (BsAb) can be used to retarget T cells irrespective of 
      their specificity to certain target cells inducing target cell lysis. We have 
      tested the efficacy of the BsAb SHR-1, directed against the T cell antigen CD3 
      and the B cell antigen CD19 to induce (malignant) B cell kill by T cells as 
      measured in a 51Cr-release assay. Two cytotoxic T cell clones (CTL), expressing 
      TCR alpha beta or TCR gamma delta, were effective in killing CD19 expressing B 
      cell lines at different stages of differentiation in the presence, but not in the 
      absence, of the BsAb. CD19- target cells were not killed. Fresh CD19+ 
      leukaemia/lymphoma cells were also efficiently killed by SHR-1 preincubated CTL 
      clones. In addition, phytohaemagglutinin (PHA) or CD3-activated IL-2 expanded 
      peripheral blood mononuclear cells (PBMC) of normal donors did so after 2 weeks 
      of stimulation. A concentration of 100 ng/ml of the BsAb was sufficient to obtain 
      optimal lysis of all target cells tested. These results show that fresh human 
      leukaemia/lymphoma cells, freshly derived from active lymphoblastic leukaemia 
      (ALL) as well as non-Hodgkin's lymphoma (NHL) patients, can be effectively killed 
      in the presence of this BsAb by activated T cells.
FAU - Haagen, I A
AU  - Haagen IA
AD  - Department of Clinical Immunology, University Hospital Utrecht, The Netherlands.
FAU - van de Griend, R
AU  - van de Griend R
FAU - Clark, M
AU  - Clark M
FAU - Geerars, A
AU  - Geerars A
FAU - Bast, B
AU  - Bast B
FAU - de Gast, B
AU  - de Gast B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD19)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (CD3 Complex)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology
MH  - Antibody Specificity
MH  - Antibody-Dependent Cell Cytotoxicity
MH  - Antigens, CD/*immunology
MH  - Antigens, CD19
MH  - Antigens, Differentiation, B-Lymphocyte/*immunology
MH  - CD3 Complex/*immunology
MH  - Cell Fusion
MH  - Clone Cells
MH  - Humans
MH  - Hybrid Cells
MH  - Interleukin-2/pharmacology
MH  - Leukemia, B-Cell/*immunology
MH  - Lymphocyte Activation/immunology
MH  - Lymphoma, B-Cell/*immunology
MH  - Rats
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
PMC - PMC1554560
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
PMCR- 1993/12/01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
PHST- 1993/12/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.1992.tb05853.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 1992 Dec;90(3):368-75. doi: 10.1111/j.1365-2249.1992.tb05853.x.